Superworth

Exelixis price to book ratio EXEL

Market value divided by the book value of the company's net assets, since 2011.

Today, Oct 23, 2026
8.7×
10-year median
4.1×
Against its 10-year history
83rd
percentile: 0 is its lowest day, 100 its highest
10-year range
2.0× to 198×
Peer median
5.1×

Exelixis' price to book ratio is 8.7× as of Oct 23, 2026.

That is above its ten-year median of 4.1×, higher than on 83% of days in the last ten years.

Over that time it ranged from 2.0× in Dec 2022 to 198× in Feb 2017.

The median for 10 biotech stocks of a similar size is 5.1×.

Price to book ratio over time

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far8.7×5.0×8.7×
20255.7×4.1×5.9×
20244.2×2.7×4.6×
20233.2×2.1×3.2×
20222.1×2.0×3.3×
20212.7×2.4×4.2×
20203.4×2.7×4.8×
20193.4×3.0×7.8×
20186.3×5.4×39.2×
201737.7×32.0×198×
2016133×107×155×
2015n/m a value too high to mean anything
2014102×8.5×113×
20138.2×2.5×8.2×
20122.4×2.4×9.4×
2011197×168×197×

Against its peers

Companies in Biotechnology nearest Exelixis' size, closest first, today.

CompanyPrice to book ratio
EXELExelixis8.7×
NBIXNeurocrine Biosciences3.9×
HALOHalozyme Therapeutics99.3×
TECHBIO-TECHNE5.4×
INCYIncyte3.7×
UTHRUnited Therapeutics3.9×
RGENRepligen4.7×
KRYSKrystal Biotech6.8×
ALNYAlnylam Pharmaceuticals22.1×
ONCBeOne Medicines8.3×
REGNRegeneron Pharmaceuticals2.6×
Peer median5.1×

What the price to book ratio tells you

Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.

Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.

More on Exelixis

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.